biologic

Humulin 70/30

insulin isophane human and insulin human

Loss of exclusivityApril 2001projected — 12-year biologic exclusivity estimate
CompanyEli Lilly and Company

Drug detail

Brand nameHumulin 70/30
Active ingredientinsulin isophane human and insulin human
Strength700UNITS/10ML (70UNITS/ML); 300UNITS/10ML (30UNITS/ML)
Dosage formInjectable Suspension
RouteSubcutaneous
ModalityBiologic
FDA approvalApril 1989
Marketing statusOTC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Humulin 70/30 patent cliff — loss of exclusivity April 2001 | CliffBio